Thesis
Design and development of an electrochemical and infrared spectroscopic medical device for serum-based cancer diagnostics
- Creator
- Rights statement
- Awarding institution
- University of Strathclyde
- Date of award
- 2020
- Thesis identifier
- T15633
- Person Identifier (Local)
- 201559983
- Qualification Level
- Qualification Name
- Department, School or Faculty
- Abstract
- Development of an integrated electrochemical and spectroscopic serum diagnosticdevice would have significant potential as a triage tool for brain cancer and Hodgkin’slymphoma in primary care settings to better inform clinical decisions and facilitateprompt referral to secondary care, whilst reducing financial and practical constraintsplaced on current diagnostic modalities. Additionally, the ability to detect IDH1molecular status from serum samples would have significant clinical value to patientsand clinicians alike, ultimately allowing earlier diagnosis and improved planning ofsurgery and treatment therapeutics. To this extent, the medical device hasdemonstrated the ability to electrochemically detect the biomarker CCL17/TARC at387-50,000pg/ml concentrations with R2 = 0.979 and limit of detection of 387pg/mlin spiked buffer samples. Thereafter, the medical device demonstrated successfuldiagnosis of Hodgkin’s lymphoma in all 11 tested clinical patient samples.Additionally, ATR-FTIR discriminated between Hodgkin’s lymphoma and healthycontrols in 200 patient samples with sensitivity of 83.2 ± 6.6% and specificity of 85.3± 8.1% with Random Forest classification, highlighting differences in proteinsecondary structures within clinical serum samples. The integrated diagnostic platformfurther demonstrated the ability to electrochemically detect IDH1-R132H proteins inspiked buffer samples at 0.05-10,000ng/ml concentrations with R2 = 0.958. However,it was not subsequently possible to detect IDH1 mutant proteins in clinical serumsamples. Nevertheless, ATR-FTIR demonstrated the ability to discriminate betweenIDH1 molecular status in 104 glioma patients through consideration of the globalmolecular signatures ofserum samples with sensitivity of 89.0 ± 11.3% and specificityof 88.2 ± 10.1% with PLS classification.
- Advisor / supervisor
- Baker, Matthew
- Dennany, Lynn
- Resource Type
- Note
- Previously held under moratorium from 17 June 2020 until 22 June 2022
- DOI
- Date Created
- 2020
- Former identifier
- 9912892791402996
Relations
Items
| Thumbnail | Title | Date Uploaded | Visibility | Actions |
|---|---|---|---|---|
|
|
PDF of thesis T15633 | 2021-07-02 | Public | Download |